<0> Pharmalucence Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients </0> Pharmalucence, Inc. () has received ...
BEDFORD, Mass.--(BUSINESS WIRE)-- Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include ...
August 7, 2009 — Adding 1% lidocaine to the radiocolloid injections used in sentinel- lymph-node (SLN) mapping in patients with early breast cancer significantly improves patient comfort during the ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.
BILLERICA — Pharmalucence Inc., whose products are used in “nuclear medicine” — diagnosing diseases using radioactive isotopes — said it has received federal Food and Drug Administration approval for ...
BILLERICA, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the indication for use of its Sulfur Colloid Injection (SCI) to include localization ...
BEDFORD, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback